Oncolytics Biotech Inc. (ONCY)

[onco_investor]

BioInvestor Forum ... Oct 29th San Francisco ONCY Presentation Link

http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=ONC.TO&item_id=1996001

Registration is free.

Brad Thompson discusses the upcoming clinical data releases

ONCY hinted that a colorectal KRAS EGFR mutation clinical trial is being written to go in parallel with the NSCLC KRAS mutation trial. Recently at ASCO KRAS positive and EGFR positive mutations have been shown to be good markers for excluding breast and colon cancer patients from using EGFR type treatments.

ONCY is in the perfect place to take advantage of this being a targeted therapy that depends on RAS mutation for its MOA. These two trials were not in the original plan for ONCY and I think they are on the ball in getting protocols written to test Reolysin in these first line therapy settings. This really elevates Reolysin to a higher level than use in a combo setting with chemo or radiation.

If you have not listened to the CEO talk about this company this presentation is worth a listen as slides are shown highlighting the dramatic effects Reolysin has had on these patients who have had refractory cancers that have not been responsive by traditional standards of care being almost fully resolved in a matter of weeks by Reolysin.

onco_investor